Maria José De Miguel

10PUBLICATIONS
129CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Apr 06, 2026
Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial.

Komal Jhaveri, Lisa D Eli, Sara A Hurvitz

|Mar 30, 2026
Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met-Targeting Antibody-Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer.

John H Strickler, Judith Raimbourg, Jonathan E Cohen

|Jul 09, 2025
Single-Agent Divarasib in Patients With <i>KRAS G12C</i>-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study.

Adrian G Sacher, Wilson H Miller, Manish R Patel

|Oct 15, 2024
Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study.

Erika Hamilton, Matthew D Galsky, Sebastian Ochsenreither

|May 06, 2024
Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer.

Hans Prenen, Sanjeev Deva, Bhumsuk Keam

|Jun 14, 2022
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors.

Tae Won Kim, Howard A Burris, Maria J de Miguel Luken

Pageof 2